Yicheng Ni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6488660/publications.pdf Version: 2024-02-01



YICHENC NI

#	Article	IF	CITATIONS
1	Development and characterization of a rat brain metastatic tumor model by multiparametric magnetic resonance imaging and histomorphology. Clinical and Experimental Metastasis, 2022, , 1.	3.3	2
2	Radioiodinated hypericin as a tracer for detection of acute myocardial infarction: SPECT-CT imaging in a swine model. Journal of Nuclear Cardiology, 2022, 29, 3432-3439.	2.1	1
3	Heterogeneity of Synchronous Lung Metastasis Calls for Risk Stratification and Prognostic Classification: Evidence from a Population-Based Database. Cancers, 2022, 14, 1608.	3.7	2
4	Have we lost an essential link between coordination chemistry and medical applications?. Coordination Chemistry Reviews, 2022, 460, 214465.	18.8	0
5	Development and characterization of a chick embryo chorioallantoic membrane (CAM) based platform for evaluation of vasoactive medications. Microvascular Research, 2022, 142, 104372.	2.5	2
6	Untiring Pursuit for Glucarate-Based Molecular Imaging Probes. Molecular Imaging and Biology, 2021, 23, 310-322.	2.6	2
7	Design and Evaluation of Rhein-Based MRI Contrast Agents for Visualization of Tumor Necrosis Induced by Combretastatin A-4 Disodium Phosphate. Molecular Imaging and Biology, 2021, 23, 220-229.	2.6	2
8	Editorial for "Tumor Stiffness Measurements on Magnetic Resonance Elastography for Single Nodular Hepatocellular Carcinomas Can Predict Tumor Recurrence after Hepatic Resection". Journal of Magnetic Resonance Imaging, 2021, 53, 597-598.	3.4	0
9	Utilisation of Chick Embryo Chorioallantoic Membrane as a Model Platform for Imaging-Navigated Biomedical Research. Cells, 2021, 10, 463.	4.1	29
10	Preparation and validation of cyclodextrin-based excipients for radioiodinated hypericin applied in a targeted cancer radiotherapy. International Journal of Pharmaceutics, 2021, 599, 120393.	5.2	5
11	Combining combretastatin A4 phosphate with ginsenoside Rd synergistically inhibited hepatocellular carcinoma by reducing HIF-11± via PI3K/AKT/mTOR signalling pathway. Journal of Pharmacy and Pharmacology, 2021, 73, 263-271.	2.4	14
12	Synthesis and Evaluation of Diindole-Based MRI Contrast Agent for In Vivo Visualization of Necrosis. Molecular Imaging and Biology, 2020, 22, 593-601.	2.6	3
13	Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI. Translational Oncology, 2020, 13, 92-101.	3.7	11
14	A newly found handbook for developing vaccines during World War II in China: the legacy of global responses to crises. Emerging Microbes and Infections, 2020, 9, 1997-1999.	6.5	0
15	Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?. Clinical Epidemiology, 2020, Volume 12, 1139-1144.	3.0	2
16	Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular Disrupting Agent Administration. International Journal of Medical Sciences, 2020, 17, 2269-2275.	2.5	5
17	Imaging Cell Death: Focus on Early Evaluation of Tumor Response to Therapy. Bioconjugate Chemistry, 2020, 31, 1025-1051.	3.6	15
18	Molecular imaging of myocardial necrosis: an updated mini-review. Journal of Drug Targeting, 2020, 28, 565-573.	4.4	8

#	Article	IF	CITATIONS
19	Radiofrequency ablation with four electrodes as a building block for matrix radiofrequency ablation: Ex vivo liver experiments and finite element method modelling. Influence of electric and activation mode on coagulation size and geometry. Surgical Oncology, 2020, 33, 145-157.	1.6	5
20	A Model In Vitro Study Using Hypericin: Tumor-Versus Necrosis-Targeting Property and Possible Mechanisms. Biology, 2020, 9, 13.	2.8	7
21	Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation. Diagnostics, 2020, 10, 78.	2.6	7
22	Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. Emerging Microbes and Infections, 2020, 9, 830-832.	6.5	13
23	Discovery of necrosis avidity of rhein and its applications in necrosis imaging. Journal of Drug Targeting, 2020, 28, 904-912.	4.4	6
24	Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study. American Journal of Cancer Research, 2020, 10, 1477-1517.	1.4	9
25	Evaluation of necrosis avidity of radioiodinated 5-hydroxytryptophan and its potential applications in myocardial infarction imaging. Chinese Chemical Letters, 2019, 30, 83-86.	9.0	1
26	Rheinâ€based necrosisâ€avid MRI contrast agents for early evaluation of tumor response to microwave ablation therapy. Magnetic Resonance in Medicine, 2019, 82, 2212-2224.	3.0	6
27	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers, 2019, 11, 1782.	3.7	53
28	Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients. Scientific Reports, 2019, 9, 9262.	3.3	18
29	Expression profiling of long noncoding RNAs associated with vasculogenic mimicry in osteosarcoma. Journal of Cellular Biochemistry, 2019, 120, 12473-12488.	2.6	22
30	Updated developments on molecular imaging and therapeutic strategies directed against necrosis. Acta Pharmaceutica Sinica B, 2019, 9, 455-468.	12.0	19
31	Evaluation of Necrosis Avidity and Potential for Rapid Imaging of Necrotic Myocardium of Radioiodinated Hypocrellins. Molecular Imaging and Biology, 2018, 20, 551-561.	2.6	3
32	The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRIâ€microangiographyâ€histopathology in rats. International Journal of Cancer, 2018, 143, 1817-1828.	5.1	17
33	Evaluation of Radioiodinated 1,4-Naphthoquinones as Necrosis Avid Agents for Rapid Myocardium Necrosis Imaging. Molecular Imaging and Biology, 2018, 20, 74-84.	2.6	5
34	First Evaluation of Radioiodinated Flavonoids as Necrosis-Avid Agents and Application in Early Assessment of Tumor Necrosis. Molecular Pharmaceutics, 2018, 15, 207-215.	4.6	5
35	A piecewise function of resistivity of liver: determining parameters with finite element analysis of radiofrequency ablation. Medical and Biological Engineering and Computing, 2018, 56, 385-394.	2.8	5
36	Synthesis and Biological Evaluation of Rhein-Based MRI Contrast Agents for in Vivo Visualization of Necrosis. Analytical Chemistry, 2018, 90, 13249-13256.	6.5	14

#	Article	IF	CITATIONS
37	Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction. European Journal of Pharmacology, 2018, 832, 145-155.	3.5	18
38	Evans Blue Dye: A Revisit of Its Applications in Biomedicine. Contrast Media and Molecular Imaging, 2018, 2018, 1-10.	0.8	104
39	Migration-inducing gene-7 independently predicts poor prognosis of human osteosarcoma and is associated with vasculogenic mimicry. Experimental Cell Research, 2018, 369, 80-89.	2.6	12
40	Monitoring reperfused myocardial infarction with delayed left ventricular systolic dysfunction in rabbits by longitudinal imaging. Quantitative Imaging in Medicine and Surgery, 2018, 8, 754-769.	2.0	5
41	Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers. World Journal of Gastroenterology, 2018, 24, 2710-2721.	3.3	7
42	Characterization of a rat orthotopic pancreatic head tumor model using threeâ€dimensional and quantitative multiâ€parametric MRI. NMR in Biomedicine, 2017, 30, e3676.	2.8	14
43	Radiolabeled Rhein as Small-Molecule Necrosis Avid Agents for Imaging of Necrotic Myocardium. Analytical Chemistry, 2017, 89, 1260-1266.	6.5	23
44	Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology. British Journal of Cancer, 2017, 117, 1529-1536.	6.4	9
45	Excretion and toxicity evaluation of ¹³¹ I-Sennoside A as a necrosis-avid agent. Xenobiotica, 2017, 47, 980-988.	1.1	2
46	A methodology for constraining power in finite element modeling of radiofrequency ablation. International Journal for Numerical Methods in Biomedical Engineering, 2017, 33, e2834.	2.1	5
47	An Imaging and Histological Study on Intrahepatic Microvascular Passage of Contrast Materials in Rat Liver. BioMed Research International, 2017, 2017, 1-11.	1.9	1
48	Visualization, Quantification and Characterization of Caerulein-Induced Acute Pancreatitis in Rats by 3.0T Clinical MRI, Biochemistry and Histomorphology. Theranostics, 2017, 7, 285-294.	10.0	11
49	Intravitreally Injected Fluid Dispersion: Importance of Injection Technique. , 2017, 58, 1434.		6
50	Pancreatic imaging: Current status of clinical practices and small animal studies. World Journal of Methodology, 2017, 7, 101-107.	3.5	6
51	Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P. Oncotarget, 2017, 8, 55204-55215.	1.8	7
52	Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease. World Journal of Gastroenterology, 2017, 23, 5499.	3.3	10
53	Discovery of Radioiodinated Monomeric Anthraquinones as a Novel Class of Necrosis Avid Agents for Early Imaging of Necrotic Myocardium. Scientific Reports, 2016, 6, 21341.	3.3	26
54	A multifunctional contrast dye for morphological research. Microscopy Research and Technique, 2016, 79, 111-121.	2.2	1

#	Article	IF	CITATIONS
55	Effects of Glycosylation on Biodistribution and Imaging Quality of Necrotic Myocardium of Iodine-131-Labeled Sennidins. Molecular Imaging and Biology, 2016, 18, 877-886.	2.6	8
56	Effects of skeleton structure on necrosis targeting and clearance properties of radioiodinated dianthrones. Journal of Drug Targeting, 2016, 24, 566-577.	4.4	5
57	Synthesis and Evaluation of ¹³¹ I-Skyrin as a Necrosis Avid Agent for Potential Targeted Radionuclide Therapy of Solid Tumors. Molecular Pharmaceutics, 2016, 13, 180-189.	4.6	11
58	Synthesis and Preclinical Evaluation of Radioiodinated Hypericin Dicarboxylic Acid as a Necrosis Avid Agent in Rat Models of Induced Hepatic, Muscular, and Myocardial Necroses. Molecular Pharmaceutics, 2016, 13, 232-240.	4.6	19
59	Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions. Oncotarget, 2016, 7, 15444-15459.	1.8	41
60	Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy. Oncotarget, 2016, 7, 51450-51461.	1.8	9
61	Rat model of cholelithiasis with human gallstones implanted in cholestasis-induced virtual gallbladder. World Journal of Methodology, 2016, 6, 154.	3.5	2
62	Prognostic significance of 18FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis. Cancer Imaging, 2015, 15, 19.	2.8	64
63	Threeâ€dimensional contrasted visualization of pancreas in rats using clinical MRI and CT scanners. Contrast Media and Molecular Imaging, 2015, 10, 379-387.	0.8	11
64	Pharmacologic Effects of Cannabidiol on Acute Reperfused Myocardial Infarction in Rabbits. Journal of Cardiovascular Pharmacology, 2015, 66, 354-363.	1.9	27
65	Differentiation between Malignant and Benign Solitary Lesions in the Liver with ¹⁸ FDG PET/CT: Accuracy of Age-related Diagnostic Standard. Journal of Cancer, 2015, 6, 40-47.	2.5	6
66	Biliary and duodenal drainage for reducing the radiotoxic risk of antineoplastic ¹³¹ I-hypericin in rat models. Experimental Biology and Medicine, 2015, 240, 1764-1773.	2.4	3
67	Evaluation of Hypericin: Effect of Aggregation on Targeting Biodistribution. Journal of Pharmaceutical Sciences, 2015, 104, 215-222.	3.3	34
68	Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model:in vivomagnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy. Journal of Drug Targeting, 2015, 23, 436-443.	4.4	8
69	Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models. Journal of Drug Targeting, 2015, 23, 371-379.	4.4	11
70	Evaluation of a metalloporphyrin (THPPMnCl) for necrosis-affinity in rat models of necrosis. Journal of Drug Targeting, 2015, 23, 926-935.	4.4	1
71	<i>Cyclocarya paliurus</i> prevents high fat diet induced hyperlipidemia and obesity in Sprague–Dawley rats. Canadian Journal of Physiology and Pharmacology, 2015, 93, 677-686. 	1.4	48
72	Antihyperlipidemic effect of Cyclocarya paliurus (Batal.) Iljinskaja extract and inhibition of apolipoprotein B48 overproduction in hyperlipidemic mice. Journal of Ethnopharmacology, 2015, 166, 286-296.	4.1	71

#	Article	IF	CITATIONS
73	PD806. Anti-Cancer Drugs, 2015, 26, 148-159.	1.4	1
74	Radiopharmaceutical evaluation of ¹³¹ I-protohypericin as a necrosis avid compound. Journal of Drug Targeting, 2015, 23, 417-426.	4.4	14
75	Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent. Journal of Drug Targeting, 2015, 23, 180-190.	4.4	8
76	Bipolar radiofrequency ablation with 2 × 2 electrodes as a building block for matrix radiofrequency ablation: <i>Ex vivo</i> liver experiments and finite element method modelling. International Journal of Hyperthermia, 2015, 31, 649-665.	2.5	20
77	Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo. Tumor Biology, 2015, 36, 8499-8510.	1.8	13
78	Re: "Endovascular Aneurysm Sealing for the Treatment of Ruptured Abdominal Aortic Aneurysms― Journal of Endovascular Therapy, 2015, 22, 956-957.	1.5	2
79	Exploring diagnostic potentials of radioiodinated sennidin A in rat model of reperfused myocardial infarction. International Journal of Pharmaceutics, 2015, 495, 31-40.	5.2	9
80	Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis. Radiologia Medica, 2015, 120, 213-221.	7.7	14
81	Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction. Drug Delivery, 2015, 22, 427-435.	5.7	12
82	Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. Oncotarget, 2015, 6, 14247-14259.	1.8	22
83	Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model. Oncotarget, 2015, 6, 26400-26410.	1.8	12
84	Necrosis Avidity of Organic Compounds: A Natural Phenomenon with Exploitable Theragnostic Potentials. Current Medicinal Chemistry, 2015, 22, 1829-1849.	2.4	12
85	Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research. Quantitative Imaging in Medicine and Surgery, 2015, 5, 708-29.	2.0	67
86	Towards Stratifying Ischemic Components by Cardiac MRI and Multifunctional Stainings in a Rabbit Model of Myocardial Infarction. Theranostics, 2014, 4, 24-35.	10.0	13
87	Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic. International Journal of Oncology, 2014, 44, 819-829.	3.3	11
88	Relationship Between ¹⁸ F-FDG Accumulation and Lactate Dehydrogenase A Expression in Lung Adenocarcinomas. Journal of Nuclear Medicine, 2014, 55, 1766-1771.	5.0	50
89	Radioiodinated Hypericin: Its Biodistribution, Necrosis Avidity and Therapeutic Efficacy are Influenced by Formulation. Pharmaceutical Research, 2014, 31, 278-290.	3.5	19
90	Hypericin as a Marker for Determination of Myocardial Viability in a Rat Model of Myocardial Infarction. Photochemistry and Photobiology, 2014, 90, 867-872.	2.5	16

#	Article	IF	CITATIONS
91	Magnetic Resonance Imaging of Cancer Therapy. , 2014, , 95-126.		Ο
92	Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. Journal of Drug Targeting, 2014, 22, 304-312.	4.4	15
93	Cyclocarya paliurus extract modulates adipokine expression and improves insulin sensitivity by inhibition of inflammation in mice. Journal of Ethnopharmacology, 2014, 153, 344-351.	4.1	48
94	InÂvivo hepatocyte MR imaging using lactose functionalized magnetoliposomes. Biomaterials, 2014, 35, 1015-1024.	11.4	32
95	Abstract 1767: Oncocidia: a small molecule dual targeting pan-anticancer theragnostic strategy. Cancer Research, 2014, 74, 1767-1767.	0.9	7
96	Necrosis-targeted combinational theragnostic approach to treat cancer. Oncotarget, 2014, 5, 2934-2946.	1.8	21
97	Targetability and Biodistribution of Radioiodinated Hypericin: Comparison between Microdosing and Carrier-Added Preparations. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 852-861.	1.7	7
98	Implications of Web of Science journal impact factor for scientific output evaluation in 16 institutions and investigators' opinion. Quantitative Imaging in Medicine and Surgery, 2014, 4, 453-61.	2.0	23
99	An overview on development and application of an experimental platform for quantitative cardiac imaging research in rabbit models of myocardial infarction. Quantitative Imaging in Medicine and Surgery, 2014, 4, 358-75.	2.0	8
100	Lipomatous metaplasia identified in rabbits with reperfused myocardial infarction by 3.0ÂT magnetic resonance imaging and histopathology. BMC Medical Imaging, 2013, 13, 18.	2.7	12
101	Detection and quantification of acute reperfused myocardial infarction in rabbits using DISA-SPECT/CT and 3.0T cardiac MRI. International Journal of Cardiology, 2013, 168, 4191-4198.	1.7	23
102	Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats. Experimental Biology and Medicine, 2013, 238, 1437-1449.	2.4	10
103	Synthesis and biological evaluation of 68Ga labeled bis-DOTA-3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) as a PET tracer for in vivo visualization of necrosis. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3216-3220.	2.2	8
104	Antihyperglycemic, antihyperlipidemic and antioxidant effects of ethanol and aqueous extracts of Cyclocarya paliurus leaves in type 2 diabetic rats. Journal of Ethnopharmacology, 2013, 150, 1119-1127.	4.1	106
105	A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [iodogen] dissolved in dimethyl sulphoxide (DMSO). Xenobiotica, 2013, 43, 730-737.	1.1	11
106	Toward Highly Potent Cancer Agents by Modulating the C-2 Group of the Arylthioindole Class of Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 123-149.	6.4	107
107	Diverse Responses to Vascular Disrupting Agent Combretastatin A4 Phosphate: A Comparative Study in Rats with Hepatic and Subcutaneous Tumor Allografts Using MRI Biomarkers, Microangiography, and Histopathology. Translational Oncology, 2013, 6, 42-50.	3.7	18
108	Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis. Nuclear Medicine and Biology, 2013, 40, 816-822.	0.6	8

#	Article	IF	CITATIONS
109	Comparative Study of Iodine-123-Labeled Hypericin and 99mTc-Labeled Hexakis [2-Methoxy Isobutyl Isonitrile] in a Rabbit Model of Myocardial Infarction. Journal of Cardiovascular Pharmacology, 2013, 62, 304-311.	1.9	17
110	Necrosis affinity evaluation of ¹³¹ I-hypericin in a rat model of induced necrosis. Journal of Drug Targeting, 2013, 21, 604-610.	4.4	19
111	Necrosis Avidity: A Newly Discovered Feature of Hypericin and its Preclinical Applications in Necrosis Imaging. Theranostics, 2013, 3, 667-676.	10.0	28
112	Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications. Journal of Cancer, 2013, 4, 133-145.	2.5	16
113	Sequential Systemic Administrations of Combretastatin A4 Phosphate and Radioiodinated Hypericin Exert Synergistic Targeted Theranostic Effects with Prolonged Survival on SCID Mice Carrying Bifocal Tumor Xenografts. Theranostics, 2013, 3, 127-137.	10.0	48
114	A Canine Model of Proximal Descending Thoracic Aortic Aneurysm Created with an Autologous Pericardial Patch. Annals of Thoracic and Cardiovascular Surgery, 2013, 19, 131-135.	0.8	6
115	Dynamic Contrast-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging Noninvasive Evaluation of Vascular Disrupting Treatment on Rabbit Liver Tumors. PLoS ONE, 2013, 8, e82649.	2.5	15
116	Bifunctional staining for <i>ex vivo</i> determination of area at risk in rabbits with reperfused myocardial infarction. World Journal of Methodology, 2013, 3, 27.	3.5	5
117	An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications. World Journal of Methodology, 2013, 3, 45.	3.5	11
118	Bipolar radiofrequency ablation with four electrodes: Ex vivo liver experiments and finite element method analysis. Influence of inter-electrode distance on coagulation size and geometry. International Journal of Hyperthermia, 2012, 28, 686-697.	2.5	21
119	Study on the Microbial Safety of an Infusion Set for Contrast-Enhanced Imaging. Investigative Radiology, 2012, 47, 247-251.	6.2	5
120	Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers. Anti-Cancer Drugs, 2012, 23, 12-21.	1.4	11
121	Continuing pursuit for ideal systemic anticancer radiotherapeutics. Investigational New Drugs, 2012, 30, 2050-2065.	2.6	8
122	Pretargeting of necrotic tumors with biotinylated hypericin using 1231-labeled avidin: evaluation of a two-step strategy. Investigational New Drugs, 2012, 30, 2132-2140.	2.6	14
123	A Novel In Vivo Rabbit Model of Abdominal Aortic Aneurysm Induced by Periarterial Incubation of Papain. Journal of Vascular and Interventional Radiology, 2012, 23, 1529-1536.	0.5	21
124	US-guided Percutaneous Microwave Coagulation of Small Breast Cancers: A Clinical Study. Radiology, 2012, 263, 364-373.	7.3	85
125	Cerebral alveolar echinococcosis: A report of two cases. Clinical Neurology and Neurosurgery, 2012, 114, 717-720.	1.4	5
126	Diffusion-weighted MR imaging allows monitoring the effect of combretastatin A4 phosphate on rabbit implanted VX2 tumor model: 12-Day dynamic results. European Journal of Radiology, 2012, 81, 578-583.	2.6	15

#	Article	IF	CITATIONS
127	Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI. PLoS ONE, 2012, 7, e41140.	2.5	15
128	Exploring Theranostic Potentials of Radioiodinated Hypericin in Rodent Necrosis Models. Theranostics, 2012, 2, 1010-1019.	10.0	44
129	Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. International Journal of Cancer, 2012, 131, E129-37.	5.1	42
130	A review on various targeted anticancer therapies. Targeted Oncology, 2012, 7, 69-85.	3.6	62
131	Topical HDL administration reduces vein graft atherosclerosis in apo E deficient mice. Atherosclerosis, 2011, 214, 271-278.	0.8	27
132	Multimodality Imaging of Endothelial Progenitor Cells with a Novel Multifunctional Probe Featuring Positive Magnetic Resonance Contrast and Near-Infrared Fluorescence. Molecular Imaging, 2011, 10, 7290.2010.00055.	1.4	5
133	Comparison Between Nonspecific and Necrosis-avid Gadolinium Contrast Agents in Vascular Disrupting Agent-Induced Necrosis of Rodent Tumors at 3.0T. Investigative Radiology, 2011, 46, 531-538.	6.2	11
134	A Dual-targeting Anticancer Approach: Soil and Seed Principle. Radiology, 2011, 260, 799-807.	7.3	81
135	Preclinical Imaging of Therapy Response Using Metabolic and Apoptosis Molecular Imaging. Molecular Imaging and Biology, 2011, 13, 995-1002.	2.6	14
136	Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1619-1627.	2.5	13
137	Radiolabeling and preliminary biological evaluation of a 99mTc(CO)3 labeled 3,3′-(benzylidene)-bis-(1H-indole-2-carbohydrazide) derivative as a potential SPECT tracer for in vivo visualization of necrosis. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 502-505.	2.2	9
138	Quantification of liver fat in mice: comparing dual-echo Dixon imaging, chemical shift imaging, and 1H-MR spectroscopy. Journal of Lipid Research, 2011, 52, 1847-1855.	4.2	30
139	Small-Animal PET of Tumor Damage Induced by Photothermal Ablation with 64Cu-Bis-DOTA-Hypericin. Journal of Nuclear Medicine, 2011, 52, 792-799.	5.0	44
140	MR Contrast Agents for Cardiac Imaging. Medical Radiology, 2011, , 31-51.	0.1	5
141	Cancer Models—Multiparametric Applications of Clinical MRI in Rodent Hepatic Tumor Model. Methods in Molecular Biology, 2011, 771, 489-507.	0.9	4
142	Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World Journal of Radiology, 2011, 3, 1.	1.1	17
143	What is the purpose of launching the <i>World Journal of Methodology</i> ?. World Journal of Methodology, 2011, 1, 1.	3.5	1
144	In Vivo Differentiation of Magnetically Labeled Mesenchymal Stem Cells Into Hepatocytes for Cell Therapy to Repair Damaged Liver. Investigative Radiology, 2010, 45, 625-633.	6.2	33

#	Article	IF	CITATIONS
145	Formulation of 3D finite elements for hepatic radiofrequency ablation. International Journal of Modelling, Identification and Control, 2010, 9, 225.	0.2	15
146	Development, evaluation and application of reperfused liver infarction in rats as a practical model for studying ischemic diseases and screening new drugs. International Journal of Modelling, Identification and Control, 2010, 9, 247.	0.2	1
147	Rodent models and magnetic resonance imaging: diagnostic and therapeutic utilities for stroke. International Journal of Modelling, Identification and Control, 2010, 9, 275.	0.2	0
148	Animal models of ischemic heart disease for in vivo cardiac MR imaging research. International Journal of Modelling, Identification and Control, 2010, 9, 288.	0.2	3
149	Choices for animal models of atherosclerosis in MR molecular imaging study. International Journal of Modelling, Identification and Control, 2010, 9, 318.	0.2	0
150	Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. European Radiology, 2010, 20, 2013-2026.	4.5	34
151	Proper definitions of MRI contrast enhancement in liver tumors. Journal of Gastroenterology, 2010, 45, 349-350.	5.1	8
152	Development and evaluation of a 68Ga labeled pamoic acid derivative for in vivo visualization of necrosis using positron emission tomography. Bioorganic and Medicinal Chemistry, 2010, 18, 5274-5281.	3.0	25
153	Automated quantitative gait analysis in animal models of movement disorders. BMC Neuroscience, 2010, 11, 92.	1.9	130
154	Is There a Decline in the Vascular Event Rate after Transient Ischemic Attack or Stroke in Antiplatelet Trials?. Cerebrovascular Diseases, 2009, 28, 439-447.	1.7	5
155	Diffusionâ€weighted MRI of hepatic tumor in rats: Comparison between in vivo and postmortem imaging acquisitions. Journal of Magnetic Resonance Imaging, 2009, 29, 621-628.	3.4	29
156	A modified rabbit model of reperfused myocardial infarction for cardiac MR imaging research. International Journal of Cardiovascular Imaging, 2009, 25, 289-298.	1.5	27
157	Tumor models and specific contrast agents for small animal imaging in oncology. Methods, 2009, 48, 125-138.	3.8	35
158	Inhibited atherosclerotic plaque formation by local administration of magnetically labeled endothelial progenitor cells (EPCs) in a rabbit model. Atherosclerosis, 2009, 205, 80-86.	0.8	43
159	Treatment of Rodent Liver Tumor With Combretastatin A4 Phosphate. Investigative Radiology, 2009, 44, 44-53.	6.2	58
160	Synthesis and preliminary biological evaluation of a99mTc-labeled hypericin derivative as a necrosis avid imaging agent. Journal of Labelled Compounds and Radiopharmaceuticals, 2008, 51, 33-40.	1.0	6
161	Preliminary in vivo evaluation of a novel 99mTc-Labeled HYNIC-cys-annexin A5 as an apoptosis imaging agent. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3794-3798.	2.2	38
162	Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?. Annals of Surgical Oncology, 2008, 15, 144-157.	1.5	138

#	Article	IF	CITATIONS
163	A Place for Radiofrequency Ablation in the Treatment of Resectable Colorectal Liver Metastases?. Annals of Surgical Oncology, 2008, 15, 2064-2065.	1.5	1
164	Murine liver implantation of radiation-induced fibrosarcoma: characterization with MR imaging, microangiography and histopathology. European Radiology, 2008, 18, 1422-1430.	4.5	22
165	A rabbit model of atherosclerosis at carotid artery: MRI visualization and histopathological characterization. European Radiology, 2008, 18, 2174-2181.	4.5	15
166	Radiofrequency Ablation versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial?. Digestive Surgery, 2008, 25, 445-460.	1.2	140
167	Hypericin as a Marker for Determination of Tissue Viability After Intratumoral Ethanol Injection in a Murine Liver Tumor Model. Academic Radiology, 2008, 15, 107-113.	2.5	41
168	Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncology Reports, 2008, , .	2.6	13
169	Metalloporphyrins and Functional Analogues as MRI Contrast Agents. Current Medical Imaging, 2008, 4, 96-112.	0.8	71
170	Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncology Reports, 2008, , .	2.6	10
171	Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncology Reports, 2008, 19, 921-6.	2.6	23
172	Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncology Reports, 2008, 19, 927-32.	2.6	28
173	In Vivo MR Tracking of Mesenchymal Stem Cells in Rat Liver after Intrasplenic Transplantation. Radiology, 2007, 245, 206-215.	7.3	57
174	Microplasmin and Tissue Plasminogen Activator: Comparison of Therapeutic Effects in Rat Stroke Model at Multiparametric MR Imaging. Radiology, 2007, 244, 429-438.	7.3	17
175	Diffusion weighted imaging in small rodents using clinical MRI scanners. Methods, 2007, 43, 12-20.	3.8	30
176	Delayed perfusion phenomenon in a rat stroke model at 1.5T MR: An imaging sign parallel to spontaneous reperfusion and ischemic penumbra?. European Journal of Radiology, 2007, 61, 70-78.	2.6	14
177	Rodent stroke induced by photochemical occlusion of proximal middle cerebral artery: Evolution monitored with MR imaging and histopathology. European Journal of Radiology, 2007, 63, 68-75.	2.6	45
178	Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[1231]iodohypericin ASPECT. European Heart Journal, 2007, 29, 260-269.	2.2	68
179	Necrosis Avidity of ^{99m} Tc(CO) ₃ -Labeled Pamoic acid Derivatives: Synthesis and Preliminary Biological Evaluation in Animal Models of Necrosis. Bioconjugate Chemistry, 2007, 18, 1924-1934.	3.6	24
180	Experimental and Clinical Radiofrequency Ablation: Proposal for Standardized Description of Coagulation Size and Geometry. Annals of Surgical Oncology, 2007, 14, 1381-1396.	1.5	62

#	Article	IF	CITATIONS
181	Evaluation of tumor affinity of mono-[123I]iodohypericin and mono-[123I]iodoprotohypericin in a mouse model with a RIF-1 tumor. Contrast Media and Molecular Imaging, 2007, 2, 113-119.	0.8	23
182	Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4001-4005.	2.2	24
183	Potentiation of Photodynamic Therapy with Hypericin by Mitomycin C in the Radiation-induced Fibrosarcoma-1 Mouse Tumor Model A¶. Photochemistry and Photobiology, 2007, 78, 278-282.	2.5	1
184	Magnetic Resonance Imaging of Acute Reperfused Myocardial Infarction: Intraindividual Comparison of ECIII-60 and Gd-DTPA in a Swine Model. CardioVascular and Interventional Radiology, 2007, 30, 248-256.	2.0	17
185	Radiofrequency Ablation: The Use of Appropriate Terms and the Citation of Prior Art. Academic Radiology, 2006, 13, 1047-1048.	2.5	1
186	In vitro labeling and MRI of mesenchymal stem cells from human umbilical cord blood. Magnetic Resonance Imaging, 2006, 24, 611-617.	1.8	88
187	Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent. European Radiology, 2006, 16, 1031-1040.	4.5	39
188	First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 595-601.	6.4	76
189	Pharmacokinetic andin vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity. Contrast Media and Molecular Imaging, 2006, 1, 267-278.	0.8	39
190	Liver Tumor Model with Implanted Rhabdomyosarcoma in Rats: MR Imaging, Microangiography, and Histopathologic Analysis. Radiology, 2006, 239, 554-562.	7.3	39
191	Electrodes and Multiple Electrode Systems for Radio Frequency Ablation: A Proposal for Updated Terminology. Advances in Experimental Medicine and Biology, 2006, 574, 57-73.	1.6	11
192	Necrosis Avid Contrast Agents. Investigative Radiology, 2005, 40, 526-535.	6.2	82
193	Local Recurrence After Hepatic Radiofrequency Coagulation. Annals of Surgery, 2005, 242, 158-171.	4.2	634
194	Dynamic susceptibility contrast-enhanced perfusion MR imaging at 1.5 T predicts final infarct size in a rat stroke model. Journal of Neuroscience Methods, 2005, 141, 55-60.	2.5	17
195	Electrodes and multiple electrode systems for radiofrequency ablation: a proposal for updated terminology. European Radiology, 2005, 15, 798-808.	4.5	54
196	Synthesis, Characterization, and Pharmacokinetic Evaluation of a Potential MRI Contrast Agent Containing Two Paramagnetic Centers with Albumin Binding Affinity. Chemistry - A European Journal, 2005, 11, 3077-3086.	3.3	47
197	Contrast Agents for Cardiac MRI. , 2005, , 33-50.		Ο
198	Effect of Vascular Targeting Agent in Rat Tumor Model: Dynamic Contrast-enhanced versus Diffusion-weighted MR Imaging. Radiology, 2005, 237, 492-499.	7.3	158

#	Article	IF	CITATIONS
199	Differentiation of Residual Tumor from Benign Periablational Tissues after Radiofrequency Ablation: The Role of MR Imaging Contrast Agents. Radiology, 2005, 237, 745-749.	7.3	5
200	Diffusion-weighted MR Imaging in Monitoring the Effect of a Vascular Targeting Agent on Rhabdomyosarcoma in Rats. Radiology, 2005, 234, 756-764.	7.3	147
201	Diffusion-Weighted Magnetic Resonance Imaging Allows Noninvasive In Vivo Monitoring of the Effects of Combretastatin A-4 Phosphate after Repeated Administration. Neoplasia, 2005, 7, 779-787.	5.3	67
202	Microplasmin Reduces Ischemic Brain Damage and Improves Neurological Function in a Rat Stroke Model Monitored With MRI. Stroke, 2004, 35, 2402-2406.	2.0	35
203	Rat cerebral ischemia induced with photochemical occlusion of proximal middle cerebral artery: a stroke model for MR imaging research. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2004, 17, 103-108.	2.0	18
204	Visualization of Stroke with Clinical MR Imagers in Rats: A Feasibility Study. Radiology, 2004, 233, 905-911.	7.3	29
205	Proper Handling of Research with Invalid Conclusions [letter]. Radiology, 2003, 229, 608-610.	7.3	3
206	Potentiation of Photodynamic Therapy with Hypericin by Mitomycin C in the Radiation-induced Fibrosarcoma–1 Mouse Tumor Model¶. Photochemistry and Photobiology, 2003, 78, 278.	2.5	9
207	Occlusive Myocardial Infarction Enhanced or Not Enhanced with Necrosis-avid Contrast Agents at MR Imaging. Radiology, 2002, 225, 603-606.	7.3	14
208	Value of T2-Weighted Magnetic Resonance Imaging Early After Myocardial Infarction in Dogs. Investigative Radiology, 2002, 37, 77-85.	6.2	54
209	Exploring Multifunctional Features of Necrosis Avid Contrast Agents. Academic Radiology, 2002, 9, S488-S490.	2.5	17
210	Necrosis-Avid Contrast Agents. Academic Radiology, 2002, 9, S98-S101.	2.5	25
211	Evaluation of radiofrequency ablation as an alternative for the treatment of brain tumor in rabbits. Journal of Neuro-Oncology, 2002, 56, 119-126.	2.9	18
212	Radiofrequency Ablation for Eradication of Pulmonary Tumor in Rabbits. Journal of Surgical Research, 2001, 99, 265-271.	1.6	127
213	MRI Contrast Enhancement of Necrosis by MP-2269 and Gadophrin-2 in a Rat Model of Liver Infarction. Investigative Radiology, 2001, 36, 97-103.	6.2	34
214	Radiofrequency Ablation for Eradication of Renal Tumor in a Rabbit Model by Using a Cooled-tip Electrode Technique. Annals of Surgical Oncology, 2001, 8, 651-657.	1.5	43
215	An ex vivo study on radiofrequency tissue ablation: increased lesion size by using an "expandable-wet" electrode. European Radiology, 2001, 11, 1841-1847.	4.5	77
216	A Comparative Study on Validation of a Novel Cooled-Wet Electrode for Radiofrequency Liver Ablation. Investigative Radiology, 2000, 35, 438-444.	6.2	81

#	Article	IF	CITATIONS
217	Manganese-Metalloporphyrin (ATN-10) as a Tumor-localizing Agent: Magnetic Resonance Imaging and Inductively Coupled Plasma Atomic Emission Spectroscopy Study with Experimental Brain Tumors. Neurosurgery, 1999, 44, 1146-1149.	1.1	8
218	Noninvasive Measurements of Infarct Size After Thrombolysis With a Necrosis-Avid MRI Contrast Agent. Circulation, 1999, 99, 690-696.	1.6	87
219	Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 tesla. Journal of Magnetic Resonance Imaging, 1999, 9, 447-453.	3.4	15
220	Enhanced Magnetic Resonance Imaging for Tissue Characterization of Liver Abnormalities with Hepatobiliary Contrast Agents. Topics in Magnetic Resonance Imaging, 1998, 9, 183.	1.2	25
221	Ex VivoExperiment on Radiofrequency Liver Ablation with Saline Infusion through a Screw-Tip Cannulated Electrode. Journal of Surgical Research, 1997, 71, 19-24.	1.6	103
222	Localization and determination of infarct size by Gd-Mesoporphyrin enhanced MRI in dogs. International Journal of Cardiovascular Imaging, 1997, 13, 499-507.	0.6	23
223	Magnetic Resonance Imaging-Histomorphologic Correlation Studies on Paramagnetic Metalloporphyrins in Rat Models of Necrosis. Investigative Radiology, 1997, 32, 770-779.	6.2	64
224	Magnetic resonance imaging of experimental tracheal transplantation. Academic Radiology, 1996, 3, 154-158.	2.5	0
225	Paramagnetic metalloporphyrins: From enhancers of malignant tumors to markers of myocardial infarcts. Academic Radiology, 1996, 3, S395-S397.	2.5	42
226	Detection and characterization of primary liver cancer in rats by MSâ€264â€enhanced MRI. Magnetic Resonance in Medicine, 1996, 35, 532-539.	3.0	14
227	Characterization of Liver Tumors with Hepatobiliary Contrast Agent Enhanced Magnetic Resonance Imaging. , 1996, , 11-24.		0
228	Localization of metalloporphyrin-induced "specific―enhancement in experimental liver tumors: Comparison of magnetic resonance imaging, microangiographic, and histologic findings. Academic Radiology, 1995, 2, 687-699.	2.5	76
229	Prolonged positive contrast enhancement with Gdâ€EOBâ€DTPA in experimental liver tumors: Potential value in tissue characterization. Journal of Magnetic Resonance Imaging, 1994, 4, 355-363.	3.4	63
230	Potential role of bile duct collaterals in the recovery of the biliary obstruction: Experimental study in rats using microcholangiography, histology, serology and magnetic resonance imaging. Hepatology, 1994, 20, 1557-1566.	7.3	24
231	The Uptake of Manganese Dipyridoxal-Diphosphate by Chemically Induced Hepatocellular Carcinoma in Rats; A Correlation between Contrast-Media-Enhanced Magnetic Resonance Imaging, Tumor Differentiation, and Vascularization. Investigative Radiology, 1993, 28, 520-527.	6.2	39
232	Mn-DPDP Enhanced MRI in Experimental Bile Duct Obstruction. Journal of Computer Assisted Tomography, 1993, 17, 290-296.	0.9	35
233	Role of Contrast Agent Perfusion and of Diffusion in the NMR Signal Enhancement of Liver Lesions. Journal of Computer Assisted Tomography, 1992, 16, 690-698.	0.9	9
234	Magnetic Resonance Imaging, Microangiography, and Histology in a Rat Model of Primary Liver Cancer. Investigative Radiology, 1992, 27, 689-697.	6.2	38